These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24497624)

  • 1. Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.
    Pawaskar M; Tuttle KR; Li Q; Best JH; Anderson PW
    Ann Pharmacother; 2014 May; 48(5):571-6. PubMed ID: 24497624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.
    Pawaskar M; Li Q; Reynolds MW
    Curr Med Res Opin; 2012 Jun; 28(6):991-7. PubMed ID: 22519390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.
    Pawaskar M; Zagar A; Sugihara T; Shi L
    J Med Econ; 2011; 14(1):16-27. PubMed ID: 21158486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
    Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
    J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.
    Muskiet MHA; Bunck MC; Heine RJ; Cornér A; Yki-Järvinen H; Eliasson B; Joles JA; Diamant M; Tonneijck L; van Raalte DH
    Diabetes Res Clin Pract; 2019 Jul; 153():14-22. PubMed ID: 31078666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
    Matyjaszek-Matuszek B; Lenart-Lipińska M; Rogalska D; Nowakowski A;
    Endokrynol Pol; 2013; 64(5):375-82. PubMed ID: 24186595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes.
    Bounthavong M; Tran JN; Golshan S; Piland NF; Morello CM; Blickensderfer A; Best JH
    Diabetes Metab; 2014 Sep; 40(4):284-91. PubMed ID: 25059703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes.
    Gordon J; McEwan P; Sabale U; Kartman B; Wolffenbuttel BH
    J Med Econ; 2016 Dec; 19(12):1167-1174. PubMed ID: 27356188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.
    Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Faries D; Engelman W; Bruhn D; Bergenstal RM
    Diabetes Obes Metab; 2012 Jul; 14(7):626-33. PubMed ID: 22321776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.
    Pawaskar MD; Blickensderfer AL; Hoogwerf BJ; Quimbo R; Wade R
    J Med Econ; 2011; 14(6):705-8. PubMed ID: 21892855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID.
    Baser O; Wei W; Baser E; Xie L
    J Med Econ; 2011; 14(6):673-80. PubMed ID: 21892858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
    Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
    Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
    J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
    Wang X; Zhang H; Zhang Q; Guan M; Sheng S; Mo W; Zou M; Li J; Bi J; Tang X; Zeng H; He J; Xu G; Li P; Xue Y
    Am J Nephrol; 2020; 51(10):806-814. PubMed ID: 32966971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
    Grimm M; Li Y; Brunell SC; Blase E
    Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
    Buse JB; Han J; Miller S; MacConell L; Pencek R; Wintle M
    Curr Med Res Opin; 2014 Jul; 30(7):1209-18. PubMed ID: 24621255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
    Levin PA; Mersey JH; Zhou S; Bromberger LA
    Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.
    Beaudet A; Palmer JL; Timlin L; Wilson B; Bruhn D; Boye KS; Lloyd A
    J Med Econ; 2011; 14(3):357-66. PubMed ID: 21563878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.
    Secnik Boye K; Matza LS; Oglesby A; Malley K; Kim S; Hayes RP; Brodows R
    Health Qual Life Outcomes; 2006 Oct; 4():80. PubMed ID: 17034640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.